Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

Accepting the bioequivalence (BE) study report, the Subject Expert Committee (SEC) functional under the Central Drugs ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Learn how semaglutide boosts health but also increases health care spending for patients. Keep reading to explore more.

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...